Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05772546
Other study ID # 22-712
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 1, 2023
Est. completion date July 31, 2025

Study information

Verified date April 2024
Source Massachusetts General Hospital
Contact Hanny Al-Samkari, MD
Phone 857-242-0719
Email hal-samkari@mgh.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. The names of the study drugs involved in this study are: - Avatrombopag (a thrombopoietin receptor agonist) - Matching placebo


Description:

This is a randomized, double-blinded, placebo-controlled, multicenter phase 2 clinical trial evaluating Avatrombopag versus placebo for Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies. Avatrombopag may increase or stimulate megakaryocytes, which aid in producing blood platelets, resulting in an increased production of platelets. - Participants will be "randomized" into one of the study groups: Group A: Avatrombopag or Group B: Matching placebo. Randomization means that a participant is put into a group by chance. - All patients who complete the study (whether they received avatrombopag or placebo) have the opportunity to receive avatrombopag to treat CIT through a special free drug program available only to the participants of this study. The U.S. Food and Drug Administration (FDA) has not approved avatrombopag for CIT, but it has been approved for other uses. Study procedures include screening for eligibility, treatment visits, and blood tests. Participants will receive the study treatment or placebo for up to seven weeks and will be followed for up to 42 days after the last dose. It is expected that about 60 people will take part in this research study. Swedish Orphan Biovitrum (Sobi), biopharmaceutical company, is supporting this research study by providing the study drugs and funding.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date July 31, 2025
Est. primary completion date March 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - A diagnosis of persistent chemotherapy-induced thrombocytopenia, as defined by a platelet count of <80,000/µL on Day 1 of a scheduled chemotherapy cycle and no platelet count above 100,000/µL in the preceding 28 days. - Age =18 years at the time of informed consent. Because no dosing or adverse event data are currently available on the use of avatrombopag for CIT in participants <18 years of age, children are excluded from this study, but may be eligible for future pediatric trials. - Receiving cytotoxic chemotherapy for a gastrointestinal malignancy, including esophageal, gastric, small bowel, hepatobiliary (cholangiocarcinoma, gallbladder carcinoma, hepatocellular carcinoma), pancreatic, or colorectal cancer. Neuroendocrine tumors and lymphomas are not eligible. Patients of any stage are eligible. - The chemotherapy regimen being used to treat the patient's gastrointestinal malignancy must be administered in 14, 21, or 28-day cycles and include at least one of the following agents: fluorouracil, capecitabine, trifluridine/tipiracil, gemcitabine, cisplatin, carboplatin, oxaliplatin, irinotecan, liposomal irinotecan, paclitaxel, nanoalbumin-bound paclitaxel, docetaxel, epirubicin, or doxorubicin. - A plan to continue the current chemotherapy regimen (the regimen that resulted in CIT) at the same dose and schedule for at least 1 more cycle if the platelet count is adequate (>100,000/µL). - Participant has not received cytotoxic chemotherapy in the 14 days before study Day 1, except for infusional fluorouracil in regimens with a 14-day cycle length or oral capecitabine in multiagent cytotoxic regimens containing capecitabine. - Eastern Cooperative Oncology Group (ECOG) performance status =2 (see Appendix B) and a life expectancy of >12 weeks at screening. - Participants must have adequate organ and marrow function as defined below. Use of standard-of-care G-CSF and/or red cell transfusions to achieve adequate ANC and hemoglobin levels is allowed. - Absolute neutrophil count (ANC) =1,500/µL - Hemoglobin =8 g/dL - AST (SGOT) and ALT (SGPT) =5 × institutional ULN - Total bilirubin =3 × institutional ULN - The effects of avatrombopag on the developing human fetus are unknown. For this reason, women of child-bearing potential and men (except for a vasectomized man with confirmed azoospermia) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for the 30 days after discontinuation of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. - Participant is willing and able to comply with the study protocol. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Participant has a history of hematologic malignancy, including leukemia, lymphoma, myeloma, myelodysplastic syndrome, or a myeloproliferative neoplasm. - Participant has known bone marrow invasion by tumor or multiple (greater than 1) bony metastatic lesions. Participants do not need to undergo screening with bone marrow biopsy or imaging to satisfy this criterion. - Participant has received prior irradiation to the pelvis of a dose of >20 Gy. - Participants with a history of a prior major venous thromboembolic event, such as a deep vein thrombosis or pulmonary embolism, or symptomatic arterial thrombotic events such as a myocardial infarction, ischemic cerebral vascular accident or transient ischemic attack will be ineligible if they have not tolerated anticoagulation therapy. If patients remain on anticoagulation or have completed the prescribed course of anticoagulation, they will be eligible for enrollment. A venous thrombotic event associated with a central venous catheter or a superficial venous thrombosis will not make the patient ineligible. - Participant has spontaneous recovery of the platelet count to >100,000/µL prior to randomization. - Participant has any known clinically significant acute or active bleeding (e.g. gastrointestinal or central nervous system) within 7 days prior to consent. - Participants who are receiving any other investigational agents or have received any other investigational agent within 30 days of study Day 1. - History of hypersensitivity reactions to avatrombopag or any of its excipients. - Participants with uncontrolled intercurrent illness, in the opinion of the investigator. - Participants with psychiatric illness/social situations that would limit compliance with study requirements, in the opinion of the investigator. - Pregnant women are excluded from this study because the effect of avatrombopag on the developing fetus are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with avatrombopag, breastfeeding should be discontinued if the mother is treated with avatrombopag. Pregnancy status will be assessed with a serum B-HCG pregnancy test in women of child-bearing potential (see Section 10 for timing). Women who are menopausal or perimenopausal will have follicle-stimulating hormone levels drawn to confirm menopausal status. - Participant has received a platelet transfusion within 3 days of study Day 1. - Participant is unable to take oral medication. - Participant has received a thrombopoietin receptor agonist (romiplostim, eltrombopag, avatrombopag, or lusutrombopag) for any reason within 14 days of study Day 1. - Participant has a history of chronic platelet disorders or thrombocytopenia due to an etiology other than CIT, in the opinion of the investigator. - Any other medical condition or factor that, in the opinion of the investigator, is likely to interfere with completion of the study.

Study Design


Intervention

Drug:
Avatrombopag
Thrombopoietin receptor agonist, tablet taken orally.
Matching Placebo
Lactose monohydrate, tablet taken orally.

Locations

Country Name City State
United States Massachusetts General Hospital Cancer Center Boston Massachusetts
United States Cleveland Clinic Cleveland Ohio
United States University of Miami Sylvester Comprehensive Cancer Center Miami Florida
United States Yale New Haven Hospital New Haven Connecticut
United States Oregon Health and Science University Hospital Portland Oregon
United States University of Washington Fred Hutchinson Cancer Center Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Hanny Al-Samkari, MD Swedish Orphan Biovitrum

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response Rate The primary endpoint of this study is the comparison of the response rate between the avatrombopag arm and the placebo arm. A response is defined as achieving a platelet count =100,000/µL within the 2 week lead-in period and then finishing at least 1 cycle of chemotherapy without CIT recurrence (no on-cycle dose-reduction or treatment delay due to thrombocytopenia and ability to receive another cycle of chemotherapy without dose-reduction or treatment delay, defined as platelet count of =100,000/µL at the start of the following cycle whether or not an additional cycle is planned). Up to 6 weeks
Primary Response Rate of CIT Treatment in Avatrombopag Defined as the composite of successful initial platelet count recovery to =100,000/µL within 15 days of initiation of study drug, plus CIT prevention for one additional chemotherapy cycle (including at the completion of that cycle/start of the following cycle). Up to 6 weeks
Primary Response Rate of CIT Treatment in Placebo Group Defined as the composite of successful initial platelet count recovery to =100,000/µL within 15 days of initiation of study drug, plus CIT prevention for one additional chemotherapy cycle (including at the completion of that cycle/start of the following cycle). Up to 6 weeks
Secondary Proportion of Platelet Count Recovery in Avatrombopag Group Assessed by the rate of initial platelet count recovery to =100,000/µL during the lead-in period At baseline, days 8 +/-1 and 15 +/-1
Secondary Proportion of Platelet Count Recovery in Placebo Group Assessed by the rate of initial platelet count recovery to =100,000/µL during the lead-in period. At baseline, days 8 +/-1 and 15 +/-1
Secondary Requirement of Platelet Transfusions in Avatrombopag Group The decision on platelet transfusion could be made either because the patient's platelet count is below a threshold, or due to physician's decision. The probability of patients requiring platelet transfusion will be estimated with a 95% confidence interval. Day 1 to 30 days post-treatment discontinuation
Secondary Requirement of Platelet Transfusions in Placebo Group The decision on platelet transfusion could be made either because the patient's platelet count is below a threshold, or due to physician's decision. The probability of patients requiring platelet transfusion will be estimated with a 95% confidence interval. Day 1 to 30 days post-treatment discontinuation
Secondary Rate of Clinically Relevant Bleeding Events in Avatrombopag Group The rate of clinically relevant bleeding will be estimated by the Kaplan-Meier curve. Bleeding events will be graded according to CTCAE and according to the modified WHO bleeding scale. Clinically significant bleeding events will be considered grade II-IV events per this scale. Day 1 to 30 days post-treatment discontinuation
Secondary Rate of Clinically Relevant Bleeding Events in Placebo Group The rate of clinically relevant bleeding will be estimated by the Kaplan-Meier curve. Bleeding events will be graded according to CTCAE and according to the modified WHO bleeding scale. Clinically significant bleeding events will be considered grade II-IV events per this scale. Day 1 to 30 days post-treatment discontinuation
Secondary Rate of Thromboembolic Events in Avatrombopag Group Thromboembolic events will be graded per CTCAE. Day 1 to 30 days post-treatment discontinuation
Secondary Rate of Thromboembolic Events in Placebo Group Thromboembolic events will be graded per CTCAE. Day 1 to 30 days post-treatment discontinuation
Secondary Rate of Serious Treatment-Emergent Adverse Events (TEAEs) in Avatromobopag Group TEAEs will be graded per CTCAE. Day 1 to 30 days post-treatment discontinuation
Secondary Rate of Serious Treatment-Emergent Adverse Events (TEAEs) in Placebo Group TEAEs will be graded per CTCAE. Day 1 to 30 days post-treatment discontinuation
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Not yet recruiting NCT05044312 - Sleep Disturbances in Surgical Patients With GI Cancers: A Quantitative and Qualitative Analysis N/A
Active, not recruiting NCT05053191 - Advancing Nursing Practices in Hospital Oncology Care N/A
Completed NCT03611309 - Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members N/A
Recruiting NCT03602677 - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage N/A
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Not yet recruiting NCT06398314 - Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors N/A
Withdrawn NCT04030624 - Remote Electronic Patient Monitoring in Gastrointestinal Cancer N/A
Completed NCT02222259 - A Feasibility Trial of Geriatric Assessment and Management for Older Cancer Patients N/A
Completed NCT02140593 - The Laparotomy Study Phase 4
Active, not recruiting NCT00716209 - Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers N/A
Recruiting NCT01484444 - Biomarker Analysis of Gastrointestinal Cancer N/A
Completed NCT02130427 - A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy N/A
Active, not recruiting NCT00710632 - Screening to Predict Weight Loss in Patients With Cancer N/A
Completed NCT00094965 - Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function Phase 2
Terminated NCT04077372 - Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers N/A
Recruiting NCT04899908 - Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases Phase 2
Recruiting NCT05429866 - Immunological Variables Associated to ICI Toxicity in Cancer Patients Phase 2
Recruiting NCT05226221 - Gastrointestinal Emergency Surgery: Evaluation of Morbidity and Mortality
Recruiting NCT03286348 - Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer N/A